Correction: Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: A systematic review with network meta-analyses (PLoS Med, (2016), 13(3), 10.1371/journal.pmed.1001971;Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses

PLoS Medicine

Volumn 13, Issue 3, 2016, Pages

  Catalá López, Ferrán ^a,b,c,d   Macías Saint Gerons, Diego ^b   González Bermejo, Diana ^b   Rosano, Giuseppe M ^e   Davis, Barry R ^f   Ridao, Manuel ^g,h   Zaragoza, Abel ^b   Montero Corominas, Dolores ^b   Tobías, Aurelio ⁱ   de la Fuente Honrubia, César ^b,j   Tabarés Seisdedos, Rafael ^a,d   Hutton, Brian ^c,k  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Alternate Representative of Spain in EMA Management Board   (Spain)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^e IRCCS SAN RAFFAELE PISANA   (Italy)

^f UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^g INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^h Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana   (Spain)

ⁱ CSIC   (Spain)

^j Area of Budgetary Stability   (Spain)

^k UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN INHIBITOR; RENIN;

ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CREATININE BLOOD LEVEL; DIABETES MELLITUS; END STAGE RENAL DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; KIDNEY DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; ADULT; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HOSPITALIZATION; KIDNEY FAILURE, CHRONIC; META ANALYSIS; MORTALITY; MYOCARDIAL INFARCTION; RENAL INSUFFICIENCY, CHRONIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY PREVENTION; STROKE;

ADULT; ANGINA PECTORIS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HEART FAILURE; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; MYOCARDIAL INFARCTION; RENAL INSUFFICIENCY, CHRONIC; RENIN; RENIN-ANGIOTENSIN SYSTEM; SECONDARY PREVENTION; STROKE;

EID: 84962068631     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/JOURNAL.PMED.1002064     Document Type: Erratum

References (87)

1. Global Burden of Disease Study 2013 CollaboratorsGlobal, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries for 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800. doi: 10.1016/S0140-6736(15)60692-426063472
2. GBD 2013 Mortality and Causes of Death CollaboratorsGlobal, regional, and national age-sex specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385:117–171. doi: 10.1016/S0140-6736(14)61682-225530442
3. GBD 2013 DALYs and HALE CollaboratorsMurray CJ, Barber RM, Foreman KJ, Abbasoglu Ozgoren A, Abd-Allah F, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015;386:2145–2191. doi: 10.1016/S0140-6736(15)61340-X26321261
4. Clarke PM, Glasziou P, Patel A, Chalmers J, Woodward M, Harrap SB, et al. Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Med. 2010;7:e1000236. doi: 10.1371/journal.pmed.100023620186272
5. Sanders GD, Coeytaux R, Dolor RJ, Hasselblad V, Patel UD, Powers B, et al. Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (ARBs), and direct renin inhibitors for treating essential hypertension: an update. 2011Jun [cited 25 Jul 2015]. Rockville (Maryland): Agency for Healthcare Research and Quality. Available: http://www.ncbi.nlm.nih.gov/books/NBK61789/.
6. American Diabetes AssociationStandards of medical care in diabetes—2015. Diabetes Care. 2015;38(Suppl 1):S1–S94.
7. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–520. doi: 10.1001/jama.2013.28442724352797
8. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035–3087. doi: 10.1093/eurheartj/eht10823996285
9. Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2014;30:485–501. doi: 10.1016/j.cjca.2014.02.00224786438
10. UK Prospective Diabetes Study GroupEfficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713–720. 9732338
11. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597–603. 9571349
12. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW, The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645–652. 9486993
13. Heart Outcomes Prevention Evaluation Study InvestigatorsEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–259. 10675071
14. Lindholm LH, Hansson L, Ekbom T, Dahlöf B, Lanke J, Linjer E, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2Study Group. J Hypertens. 2000;18:1671–1675.
15. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A, CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24:2091–2096. 11723089
16. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860. 11565517
17. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878. 11565519
18. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869. 11565518
19. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004–1010. 11937179
20. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iamathi E, Kostis JB, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:1401–1409. 15983290
21. Patel A, ADVANCE Collaborative GroupMacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–840. 17765963
22. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–2213. doi: 10.1056/NEJMoa120879923121378
23. Cheng J, Zhang W, Zhang X, Han F, Li X, He X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174:773–785. doi: 10.1001/jamainternmed.2014.34824687000
24. Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Jung KY, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis. BMJ. 2013;347:f6008. doi: 10.1136/bmj.f600824157497
25. Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J, Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 2012;55:566–578. doi: 10.1007/s00125-011-2398-822189484
26. Nakao YM, Teramukai S, Tanaka S, Yasuno S, Fujimoto A, Kasahara M, et al. Effects of renin-angiotensin system blockades on cardiovascular outcomes in patients with diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2012;96:68–75. doi: 10.1016/j.diabres.2011.11.02522197527
27. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026–2033. 16338452
28. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC, Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004;329:828. 15459003
29. Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW, et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2015;1:CD008170. doi: 10.1002/14651858.CD008170.pub225577154
30. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH, Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomized trials. BMJ. 2013;346:f360. doi: 10.1136/bmj.f36023358488
31. Savarese G, Costanzo P, Cleland JG, Vassallo E, Ruggiero D, Rosano G, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013;61:131–142. doi: 10.1016/j.jacc.2012.10.01123219304
32. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33:2088–2097. doi: 10.1093/eurheartj/ehs07522511654
33. Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M, Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med. 2011;171:384–394. doi: 10.1001/archinternmed.2010.42721059964
34. Bangalore S, Kumar S, Wetterslev J, Messerli FH, Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ. 2011;342:d2234. doi: 10.1136/bmj.d223421521728
35. Kuenzli A, Bucher HC, Anand I, Arutiunov G, Kum LC, McKelvie R, et al. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS ONE. 2010;5:e9946. doi: 10.1371/journal.pone.000994620376345
36. Baker WL, Coleman CI, Kluger J, Reinhart KM, Talati R, Quercia R, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med. 2009;151:861–871. doi: 10.7326/0003-4819-151-12-200912150-0016220008762
37. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534–2544. 12759325
38. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031. 15207952
39. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–1906. 14610160
40. ONTARGET InvestigatorsYusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559. doi: 10.1056/NEJMoa080131718378520
41. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–553. doi: 10.1016/S0140-6736(08)61236-218707986
42. Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047–2056. doi: 10.1016/S0140-6736(14)62459-426009228
43. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.100009719621072
44. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777–784. doi: 10.7326/M14-238526030634
45. Sampson M, Shojania KG, McGowan J, Daniel R, Rader T, Iansavichene AE, et al. Surveillance search techniques identified the need to update systematic reviews. J Clin Epidemiol. 2008;61:755–762. doi: 10.1016/j.jclinepi.2007.10.00318586179
46. Hutton B, Tetzlaff J, Yazdi F, Thielman J, Kanji S, Fergusson D, et al. Comparative effectiveness of monotherapies and combination therapies for patients with hypertension: protocol for a systematic review with network meta-analyses. Syst Rev. 2013;2:44. doi: 10.1186/2046-4053-2-4423809864
47. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225–1237. doi: 10.1056/NEJMoa080459318753639
48. Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) InvestigatorsYusuf S, Teo K, Anderson C, Pogue J, Dyal L, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174–1183. doi: 10.1016/S0140-6736(08)61242-818757085
49. Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009;151:1–10,W1-W2. 19451556
50. Haller H, Ito S, Izzo JL, JrJanuszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907–917. doi: 10.1056/NEJMoa100799421388309
51. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML, et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J. 2005;26:1369–1378. 15860521
52. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372:1394–1402. doi: 10.1016/S0140-6736(08)61412-918823656
53. Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med. 2009;151:11–20,W3-W4. 19451554
54. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebo-controlled trial. Lancet. 2008;372:1385–1393. doi: 10.1016/S0140-6736(08)61411-718823658
55. Cohn JN, Tognoni G, Valsartan Heart Failure Trial InvestigatorsA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675. 11759645
56. Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309:1125–1135. doi: 10.1001/jama.2013.195423478743
57. Nakao K, Hirata M, Oba K, Yasuno S, Ueshima K, Fujimoto A, et al. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Hypertens Res. 2010;33:600–606. doi: 10.1038/hr.2010.3820379187
58. Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, et al. Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. J Hypertens. 2014;32:2054–2063. doi: 10.1097/HJH.000000000000028124999799
59. Matsui K, Kim-Mitsuyama S, Ogawa H, Jinnouchi T, Jinnouchi H, Arakawa K, et al. Sex differences in response to angiotensin II receptor blocker-based therapy in elderly, high-risk, hypertensive Japanese patients: a subanalysis of the OSCAR study. Hypertens Res. 2014;37:526–532. doi: 10.1038/hr.2014.2324599010
60. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d592822008217
61. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–406. doi: 10.1016/j.jclinepi.2010.07.01521208779
62. Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630. doi: 10.1136/bmj.g563025252733
63. Rochwerg B, Alhazzani W, Sindi A, Heels-Ansdell D, Thabane L, Fox-Robichaud A, et al. Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med. 2014;161:347–355. doi: 10.7326/M14-017825047428
64. Cochran WG, The combination of estimates from different experiments. Biometrics. 1954;10:101–129.
65. Higgins JP, Thompson SG, Deeks JJ, Altman DG, Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. 12958120
66. Ioannidis JP, Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ. 2009;181:488–493. doi: 10.1503/cmaj.08108619654195
67. Catalá-López F, Tobías A, Cameron C, Moher D, Hutton B, Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int. 2014;34:1489–1496. doi: 10.1007/s00296-014-2994-224691560
68. Cipriani A, Higgins JP, Geddes JR, Salanti G, Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159:130–137. doi: 10.7326/0003-4819-159-2-201307160-0000823856683
69. Catalá-López F, Hutton B, Moher D, The transitive property across randomized controlled trials: if B is better than A, and C is better than B, will C be better than A?Rev Esp Cardiol. 2014;67:597–602. doi: 10.1016/j.rec.2013.11.01625037537
70. Dias S, Sutton AJ, Ades AE, Welton NJ, Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607–617. doi: 10.1177/0272989X1245872423104435
71. Gelman A, Rubin DB, Inference from iterative simulation using multiple sequences. Stat Sci. 1992;7:457–472.
72. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE, Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33:641–656. doi: 10.1177/0272989X1245584723804508
73. Salanti G, Ades AE, Ioannidis JP, Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163–171. doi: 10.1016/j.jclinepi.2010.03.01620688472
74. Dias S, Sutton AJ, Welton NJ, Ades AE, Evidence synthesis for decision making 3: heterogeneity—subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making. 2013;33:618–640. doi: 10.1177/0272989X1348515723804507
75. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892–1903. doi: 10.1056/NEJMoa130315424206457
76. Verma S, Strauss M, Angiotensin receptor blockers and myocardial infarction. BMJ. 2004;329:1248–1249. 15564232
77. Strauss MH, Hall AS, Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114:838–854. 16923768
78. Hall AS, Strauss MH, More about the “ARB MI paradox”. Heart. 2007;93:1011–1014. 17699164
79. Hobbs FD, Angiotensin receptor blockers and cardiovascular outcomes. BMJ. 2011;342:d2193. doi: 10.1136/bmj.d219321527455
80. Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54:2978–2986. doi: 10.1007/s00125-011-2325-z21993710
81. US Food and Drug Safety Administration. FDA drug safety communication: FDA review of cardiovascular risks for diabetics taking hypertension drug olmesartan not conclusive; label updates required. 2014 Jun 6 [cited 12 Jun 2015]. Available: http://www.fda.gov/Drugs/DrugSafety/ucm402323.htm.
82. European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). Minutes of the Meeting—29–31 October 2012. 2012 Nov 29 [cited 12 Jun 2015]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2012/12/WC500135712.pdf.
83. European Medicines Agency. European Medicines Agency recommends new contraindications and warnings for aliskiren-containing medicines. 2012 Feb 17 [cited 2 Jun 2015]. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/02/news_detail_001446.jsp&mid=WC0b01ac058004d5c1.
84. Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail. 2011;13:107–114. doi: 10.1093/eurjhf/hfq21221169387
85. Cleland JG, Clark AL, Costanzo P, Francis DP, Diabetes, aliskiren, and heart failure: let’s bring ASTRONAUT down to earth. Eur Heart J. 2013;34:3097–3099. doi: 10.1093/eurheartj/eht36623999453
86. Montori VM, Permanyer-Miralda G, Ferreira-González I, Busse JW, Pacheco-Huergo V, Bryant D, et al. Validity of composite end points in clinical trials. BMJ. 2005;330:594–596. 15761002
87. Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ. 2007;334:786. 17403713